MAP2K1 and hypertrophic cardiomyopathy: More than 90% of NS patients with mutations in conserved region 2 of RAF1 suffer from severe hypertrophic cardiomyopathy, resulting from abnormal ERK5 and MEK1/2 signalling [6].